In a rare move Columbia issues Compulsor
Post# of 148109
The move could drastically lower the cost of DoluteGravir, which is manufactured by ViiV Healthcare an HIV-focused drug company operated by GSK...who is obviously disappointed by the decision.
It seems dialogue is ongoing. The "Intellectual Property Rights are the foundation for Innovation"...came immediately out of the playbook.
On another front... GSK accuses PFizer and BioNTech of mRNA patent infringement...When it rains ...it pours.
O